

Pregabalin for Treatment of Generalized Anxiety Disorder

Archives of General Psychiatry

62, 1022

DOI: [10.1001/archpsyc.62.9.1022](https://doi.org/10.1001/archpsyc.62.9.1022)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Evidence-based pharmacotherapy of Generalized Anxiety Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 293-302.	1.0	105
2	A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. <i>Psychopharmacology</i> , 2005, 183, 133-143.	1.5	95
3	Pregabalin: A New Neuromodulator with Broad Therapeutic Indications. <i>Annals of Pharmacotherapy</i> , 2005, 39, 2029-2037.	0.9	163
4	Sleep and Anxiety Disorders. <i>Psychiatric Clinics of North America</i> , 2006, 29, 1047-1058.	0.7	124
5	GABA receptors as targets for novel anxiolytic drugs. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 231-237.	1.3	26
6	Pregabalin. <i>CNS Drugs</i> , 2006, 20, 685-693.	2.7	48
7	Generalized anxiety disorder: how to treat, and for how long?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 10-15.	1.2	2
8	P.4.c.005 Pregabalin's efficacy in achieving remission in outpatients with generalized anxiety disorder. <i>European Neuropsychopharmacology</i> , 2006, 16, S466-S467.	0.3	0
10	Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: A comparative short-term study. <i>Epilepsy and Behavior</i> , 2006, 9, 424-431.	0.9	51
11	Newer anticonvulsants in the treatment of anxiety disorders. <i>The Cochrane Library</i> , 2006, , .	1.5	0
13	Pregabalin for neuropathic pain based on recent clinical trials. <i>Current Pain and Headache Reports</i> , 2006, 10, 179-184.	1.3	24
14	Management of psychiatric comorbidity in fibromyalgia. <i>Current Psychiatry Reports</i> , 2006, 8, 241-245.	2.1	8
15	Pregabalin action at a model synapse: Binding to presynaptic calcium channel $\alpha_2\text{-}\beta_1$ subunit reduces neurotransmission in mice. <i>European Journal of Pharmacology</i> , 2006, 553, 82-88.	1.7	59
16	Pregabalin for the treatment of generalised anxiety disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2139-2154.	0.9	57
17	Sleep Disturbances in Patients With Psychiatric Illnesses. <i>Journal of Pharmacy Practice</i> , 2006, 19, 369-378.	0.5	3
18	Oesophagogastric fistula: a post-operative complication. <i>Gut</i> , 2007, 56, 1225-1225.	6.1	0
19	Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. <i>Current Opinion in Anaesthesiology</i> , 2007, 20, 456-472.	0.9	200
20	Emerging anxiolytics. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 541-554.	1.0	19

#	ARTICLE	IF	CITATIONS
21	Effect of a second-generation $\alpha_2\alpha$ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. <i>Gut</i> , 2007, 56, 1218-1225.	6.1	174
22	The Role of Anticonvulsant Drugs in Anxiety Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 263-272.	0.7	181
23	Efficacy and Tolerability of a Standardized Herbal Product from <i>Galphimia glauca</i> on Generalized Anxiety Disorder. A Randomized, Double-Blind Clinical Trial Controlled with Lorazepam. <i>Planta Medica</i> , 2007, 73, 713-717.	0.7	61
24	Dose-response Relationship of Pregabalin in Patients with Generalized Anxiety Disorder. A Pooled Analysis of Four Placebo-controlled Trials. <i>Pharmacopsychiatry</i> , 2007, 40, 163-168.	1.7	87
25	Pregabalin in the treatment of depression. <i>Journal of Psychopharmacology</i> , 2007, 21, 883-884.	2.0	22
26	Pregabalin: Its Pharmacology and Use in Pain Management. <i>Anesthesia and Analgesia</i> , 2007, 105, 1805-1815.	1.1	292
27	Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. <i>International Clinical Psychopharmacology</i> , 2007, 22, 167-174.	0.9	268
28	Do Surgical Patients Benefit from Perioperative Gabapentin/Pregabalin? A Systematic Review of Efficacy and Safety. <i>Anesthesia and Analgesia</i> , 2007, 104, 1545-1556.	1.1	457
30	Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam. <i>Yearbook of Psychiatry and Applied Mental Health</i> , 2007, 2007, 231-232.	0.1	0
31	Anticonvulsants in sports: Ethical considerations. <i>Epilepsy and Behavior</i> , 2007, 10, 268-271.	0.9	11
32	Ca ²⁺ channel $\alpha_2\delta$ ligands: novel modulators of neurotransmission. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 75-82.	4.0	395
33	Pharmacologic management of neuropathic pain: Evidence-based recommendations. <i>Pain</i> , 2007, 132, 237-251.	2.0	1,740
34	Pregabalin: A novel β -aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. <i>Clinical Therapeutics</i> , 2007, 29, 26-48.	1.1	259
36	P.4.b.012 Chronic diazepam treatment and reactivity of 5-HT _{1A} and 5-HT _{2A} receptors in the dorsal periaqueductal gray matter. <i>European Neuropsychopharmacology</i> , 2007, 17, S516-S517.	0.3	0
38	P.4.c.002 Quetiapine augmentation of SSRIs for treatment refractory social anxiety disorder. <i>European Neuropsychopharmacology</i> , 2007, 17, S517-S518.	0.3	2
39	Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy. <i>Drug Safety</i> , 2007, 30, 555-567.	1.4	220
40	Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 769-781.	1.4	95
42	What psychotherapists should know about pharmacotherapies for bipolar disorder. <i>Journal of Clinical Psychology</i> , 2007, 63, 475-490.	1.0	2

#	ARTICLE	IF	CITATIONS
43	Use of antiepileptic drugs for nonepileptic conditions: Psychiatric disorders and chronic pain. <i>Neurotherapeutics</i> , 2007, 4, 75-83.	2.1	139
44	The Effect of Anxiety and Depression on Improvements in Pain in a Randomized, Controlled Trial of Pregabalin for Treatment of Fibromyalgia. <i>Pain Medicine</i> , 2007, 8, 633-638.	0.9	89
45	SATELLITE SYMPOSIA. <i>European Journal of Neurology</i> , 2007, 14, 321-327.	1.7	33
46	Residual symptoms and recurrence during maintenance treatment of late-life depression. <i>Journal of Affective Disorders</i> , 2007, 103, 77-82.	2.0	131
48	Glutamate and anxiety disorders. <i>Current Psychiatry Reports</i> , 2007, 9, 278-283.	2.1	41
49	Efficacy and safety of pregabalin in alcohol dependence. <i>Advances in Therapy</i> , 2008, 25, 608-618.	1.3	48
50	Novel treatment approaches for refractory anxiety disorders. <i>Depression and Anxiety</i> , 2008, 25, 467-476.	2.0	66
51	Anxiety disorders: a comprehensive review of pharmacotherapies. <i>Mount Sinai Journal of Medicine</i> , 2008, 75, 248-262.	1.9	130
52	Effects of pregabalin on visceral pain responses and colonic compliance in rats. <i>British Journal of Pharmacology</i> , 2008, 155, 407-416.	2.7	54
53	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 248-312.	1.3	661
54	Gabapentin in traumatic nerve injury pain: A randomized, double-blind, placebo-controlled, cross-over, multi-center study. <i>Pain</i> , 2008, 138, 255-266.	2.0	116
55	Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies. <i>European Neuropsychopharmacology</i> , 2008, 18, 422-430.	0.3	81
56	Brief post-stressor treatment with pregabalin in an animal model for PTSD: Short-term anxiolytic effects without long-term anxiogenic effect. <i>European Neuropsychopharmacology</i> , 2008, 18, 653-666.	0.3	38
58	Sleep and Anxiety Disorders. <i>Sleep Medicine Clinics</i> , 2008, 3, 261-268.	1.2	69
59	Novel Treatment Approaches for Refractory Anxiety Disorders. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 182 T	0.4	5
60	Does Acute Treatment with Sedatives/Hypnotics for Anxiety in Depressed Patients Affect Suicide Risk? A Literature Review. <i>Annals of Clinical Psychiatry</i> , 2008, 20, 157-169.	0.6	50
61	Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. <i>British Journal of Psychiatry</i> , 2008, 193, 389-394.	1.7	119
62	Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy. <i>Medical Psychiatry</i> , 2008, , 207-250.	0.2	0

#	ARTICLE	IF	CITATIONS
63	Long-term efficacy of pregabalin in generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2008, 23, 18-28.	0.9	108
65	The role of duloxetine in the treatment of anxiety disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 929.	1.0	15
67	The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going?. <i>CNS Spectrums</i> , 2009, 14, 5-12.	0.7	6
68	Recent advances in bipolar disorder pharmacotherapy: focus on bipolar depression and rapid cycling. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 423-434.	1.3	3
69	Pregabalin in the Treatment of Schizophrenic Anxiety. <i>Pharmacopsychiatry</i> , 2009, 42, 124-125.	1.7	19
70	Relationship between adjunctive medications for anxiety and time spent ill in patients with bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2009, 13, 70-77.	1.2	4
71	Pregabalin (Lyrica®; Pfizer, Inc.). <i>Issues in Mental Health Nursing</i> , 2009, 30, 138-139.	0.6	0
72	Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model. <i>Journal of Psychopharmacology</i> , 2009, 23, 867-873.	2.0	40
73	The anti-epileptic drug lacosamide (Vimpat®) has anxiolytic property in rodents. <i>European Journal of Pharmacology</i> , 2009, 624, 1-9.	1.7	19
74	Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. <i>Veterinary Anaesthesia and Analgesia</i> , 2009, 36, 574-580.	0.3	54
75	Anxiolytic profile of pregabalin on elicited hippocampal theta oscillation. <i>Neuropharmacology</i> , 2009, 56, 379-385.	2.0	39
76	Pharmacological Treatment of Generalized Anxiety Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2009, 2, 453-467.	0.8	25
77	Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1147-1158.	1.4	38
78	The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. <i>International Clinical Psychopharmacology</i> , 2009, 24, 214-222.	0.9	42
79	Comments on "Clinical Trials of Antidepressants: Time to Shift to a New Model" by Dr Katz. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 197-198.	0.7	0
80	Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. <i>International Clinical Psychopharmacology</i> , 2009, 24, 87-96.	0.9	82
81	Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. <i>International Clinical Psychopharmacology</i> , 2009, 24, 126-132.	0.9	12
82	All Results Count. <i>Anesthesia and Analgesia</i> , 2009, 108, 1058-1061.	1.1	2

#	ARTICLE	IF	CITATIONS
83	The Effect of Pregabalin on Preoperative Anxiety and Sedation Levels: A Dose-Ranging Study. <i>Anesthesia and Analgesia</i> , 2009, 108, 1140-1145.	1.1	122
84	Psychiatric Aspects of HIV Spectrum Disease. <i>Focus (American Psychiatric Publishing)</i> , 2009, 7, 303-310.	0.4	7
85	Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. <i>International Clinical Psychopharmacology</i> , 2009, 24, 29-33.	0.9	21
86	New Prospects for the Drug Treatment of Generalized Anxiety Disorder — A Systematic Review. <i>Current Drug Therapy</i> , 2010, 5, 86-94.	0.2	2
87	Adjunctive Use of Atypical Antipsychotics for Treatment-Resistant Generalized Anxiety Disorder. <i>Pharmacotherapy</i> , 2010, 30, 942-951.	1.2	26
88	Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. <i>Human Psychopharmacology</i> , 2010, 25, 268-275.	0.7	44
89	Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. <i>Addiction</i> , 2010, 105, 288-299.	1.7	58
90	Pharmacotherapy Update: Pregabalin in the Treatment of Generalized Anxiety Disorder. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S1103.	0.4	5
91	Advances in the Management of Treatment-Resistant Anxiety Disorders. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	13
92	Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. <i>Journal of Psychopharmacology</i> , 2010, 24, 1367-1374.	2.0	54
93	Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 229.	1.0	61
94	ÂPregabalin for generalised anxiety disorder. <i>Drug and Therapeutics Bulletin</i> , 2010, 48, 19-22.	0.3	1
95	Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 305.	1.0	116
96	Modulation of ion channels in clinical psychopharmacology: adults and younger people. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 397-416.	1.3	1
97	Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 941-950.	1.0	140
98	Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). <i>Journal of Psychopharmacology</i> , 2010, 24, 3-26.	2.0	48
99	Preemptive Multimodal Pain Regimen Reduces Opioid Analgesia for Patients Undergoing Robotic-assisted Laparoscopic Radical Prostatectomy. <i>Urology</i> , 2010, 76, 1122-1124.	0.5	73
100	Is antiepileptic drug use related to depression and suicidal ideation among patients with epilepsy?. <i>Epilepsy and Behavior</i> , 2010, 19, 494-500.	0.9	20

#	ARTICLE	IF	CITATIONS
101	Identifying HAMÅ€A cutoffs for mild, moderate, and severe generalized anxiety disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2010, 19, 223-232.	1.1	143
102	Relationships Among Pain and Depressive and Anxiety Symptoms in Clinical Trials of Pregabalin in Fibromyalgia. <i>Psychosomatics</i> , 2010, 51, 489-497.	2.5	32
103	Pharmacological treatment of generalized anxiety disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2457-2467.	0.9	61
104	Pain Management Principles. <i>Current Problems in Cancer</i> , 2011, 35, 317-324.	1.0	0
105	Postoperative Respiratory Depression Associated with Pregabalin: A Case Series and a Preoperative Decision Algorithm. <i>Pain Research and Management</i> , 2011, 16, 353-356.	0.7	37
106	Generalized Anxiety Disorder in Adults: Focus on Pregabalin. <i>Clinical Medicine Insights Psychiatry</i> , 2011, 3, CMPsy.S5069.	0.4	2
107	A Meta-Analysis of the Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 558-566.	0.9	30
108	The adverse event profile of pregabalin: A systematic review and metaÅ€analysis of randomized controlled trials. <i>Epilepsia</i> , 2011, 52, 826-836.	2.6	165
109	Aripiprazole: A clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. <i>Journal of Affective Disorders</i> , 2011, 128, S11-S20.	2.0	27
110	Evidence-based pharmacological treatment of generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 697-710.	1.0	125
111	Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2011, 342, d1199-d1199.	2.4	236
112	Modeling Dropout From Adverse Event Data: Impact of Dosing Regimens Across Pregabalin Trials in the Treatment of Generalized Anxiety Disorder. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 706-718.	1.0	6
113	Anxiolytic-Like Activity of Pregabalin in the Vogel Conflict Test in Î±₂Î³-1 (R217A) and Î±₂Î³-2 (R279A) Mouse Mutants. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 615-621.	1.3	50
114	Validating the inhalation of 7.5% CO₂ in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). <i>Journal of Psychopharmacology</i> , 2011, 25, 1192-1198.	2.0	36
115	Clinical Trial Simulations. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , .	0.2	22
116	Coanalgesics for Chronic Pain Therapy: A Narrative Review. <i>Postgraduate Medicine</i> , 2011, 123, 140-150.	0.9	14
117	Pregabalin Influences Insula and Amygdala Activation During Anticipation of Emotional Images. <i>Neuropsychopharmacology</i> , 2011, 36, 1466-1477.	2.8	52
118	Pregabalin: Dose-Response Relationship in Generalized Anxiety Disorder. <i>Pharmacopsychiatry</i> , 2012, 45, 51-56.	1.7	10

#	ARTICLE	IF	CITATIONS
119	Pregabalin Beneficial Effects on Sleep Quality or Health-Related Quality of Life Are Poorly Correlated With Reduction on Pain Intensity After an 8-Week Treatment Course. <i>Clinical Neuropharmacology</i> , 2012, 35, 21-24.	0.2	11
120	Recognizing anxiety disorders. <i>Nurse Practitioner</i> , 2012, 37, 35-42.	0.2	1
121	Evidence-Based Review of Clinical Outcomes of Guideline-Recommended Pharmacotherapies for Generalized Anxiety Disorder. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 470-478.	0.9	21
122	Principles of drug treatment in adults. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 108, 683-698.	1.0	6
123	Asymmetric timeâ€dependent activation of right central amygdala neurones in rats with peripheral neuropathy and pregabalin modulation. <i>European Journal of Neuroscience</i> , 2012, 36, 3204-3213.	1.2	92
124	Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?. <i>European Neuropsychopharmacology</i> , 2012, 22, 137-142.	0.3	21
125	A critical test of the hippocampal theta model of anxiolytic drug action. <i>Neuropharmacology</i> , 2012, 62, 155-160.	2.0	36
126	The effect of pregabalin on sensorimotor gating in â€lowâ€™ gating humans and mice. <i>Neuropharmacology</i> , 2012, 63, 480-485.	2.0	16
127	Pregabalin for the Treatment of Generalized Anxiety Disorder. <i>Annals of Pharmacotherapy</i> , 2012, 46, 424-429.	0.9	62
128	Elucidating the Mechanism of Action of Pregabalin. <i>CNS Drugs</i> , 2012, 26, 637-648.	2.7	50
129	Anxiolytic Use in the Postoperative Care Unit. <i>Anesthesiology Clinics</i> , 2012, 30, 467-480.	0.6	7
130	Generalized anxiety disorder. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 343-362.	1.0	20
133	Pregabalin effects on neural response to emotional faces. <i>Frontiers in Human Neuroscience</i> , 2012, 6, 42.	1.0	20
134	Evidence-based pharmacotherapy of generalized anxiety disorder. , 0, , 110-127.		1
135	GENERALIZABILITY OF CLINICAL TRIAL RESULTS FOR GENERALIZED ANXIETY DISORDER TO COMMUNITY SAMPLES. <i>Depression and Anxiety</i> , 2012, 29, 614-620.	2.0	56
136	EXTENDED RELEASE QUETIAPINE FUMARATE IN MAJOR DEPRESSIVE DISORDER: ANALYSIS IN PATIENTS WITH ANXIOUS DEPRESSION. <i>Depression and Anxiety</i> , 2012, 29, 574-586.	2.0	32
137	The adverse event profile of pregabalin across different disorders: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 903-912.	0.8	31
138	Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. <i>Psychopharmacology</i> , 2012, 220, 87-96.	1.5	29

#	ARTICLE	IF	CITATIONS
139	The Anxiolytic Potential and Psychotropic Side Effects of an <i>Echinacea</i> Preparation in Laboratory Animals and Healthy Volunteers. <i>Phytotherapy Research</i> , 2013, 27, 54-61.	2.8	22
140	Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat. <i>Addiction Biology</i> , 2013, 18, 644-653.	1.4	32
141	A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. <i>Cost Effectiveness and Resource Allocation</i> , 2013, 11, 8.	0.6	6
142	Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders – Results of an open-label, parallel group, investigator-initiated, proof-of-concept study. <i>Epilepsy and Behavior</i> , 2013, 29, 298-304.	0.9	16
143	Do Benzodiazepines Still Deserve a Major Role in The Treatment of Psychiatric Disorders? A Critical Reappraisal. <i>European Psychiatry</i> , 2013, 28, 7-20.	0.1	164
144	Cross-Over, Open-Label Trial of the Effects of Gabapentin versus Pregabalin on Painful Peripheral Neuropathy and Health-Related Quality of Life in Haemodialysis Patients. <i>Clinical Drug Investigation</i> , 2013, 33, 401-408.	1.1	26
145	Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins. <i>Bipolar Disorders</i> , 2013, 15, 813-823.	1.1	18
146	The Cost Effectiveness of Pharmacological Treatments for Generalized Anxiety Disorder. <i>Pharmacoeconomics</i> , 2013, 31, 317-333.	1.7	14
147	Glutamate-based anxiolytic ligands in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1007-1022.	1.9	17
148	The best next drug in the course of generalized anxiety disorders: the ‘PN-GAD-algorithm’ International Journal of Psychiatry in Clinical Practice, 2013, 17, 78-89.	1.2	8
149	A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. <i>Burns</i> , 2013, 39, 24-29.	1.1	55
150	Understanding the pharmacokinetics of anxiolytic drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 423-440.	1.5	75
151	The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 332-339.	4.0	251
152	Effects of pregabalin on sleep in generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 925-936.	1.0	40
153	Successful Treatment of a Patient With Long-Standing History of Catatonic Schizophrenia With Pregabalin. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 814-816.	0.7	1
154	Adjunctive Pregabalin in Partial Responders With Major Depressive Disorder and Residual Anxiety. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 95-98.	0.7	11
155	Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. <i>Current Medical Research and Opinion</i> , 2013, 29, 1223-1230.	0.9	28
156	The Diagnosis and Treatment of Generalized Anxiety Disorder. <i>Deutsches A&#x0308;rzblatt International</i> , 2013, 110, 300-9; quiz 310.	0.6	47

#	ARTICLE	IF	CITATIONS
157	Pregabalin for the treatment of generalized anxiety disorder: an update. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 883.	1.0	65
158	Generalised anxiety disorder. <i>South African Journal of Psychiatry</i> , 2013, 19, 5.	0.2	6
159	Treatment of Generalized Anxiety Disorders: Unmet Needs. , 2013, , .		1
160	Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 155-166.	1.3	17
161	Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 685-695.	1.0	31
162	Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 252-262.	0.9	5
163	Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: A Study of Monographs and Published Literature. <i>Drugs and Aging</i> , 2014, 31, 55-65.	1.3	7
164	How well do randomized controlled trial data generalize to "real-world" clinical practice settings? A comparison of two generalized anxiety disorder studies. <i>European Neuropsychopharmacology</i> , 2014, 24, 125-132.	0.3	8
165	Neuropathic Pain and Pharmacological Treatment. <i>Pain Practice</i> , 2014, 14, 283-295.	0.9	30
166	A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. <i>Sleep Medicine Reviews</i> , 2014, 18, 261-271.	3.8	45
167	Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 29-38.	1.4	9
168	Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i> , 2014, 14, S1.	1.1	569
169	Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder. <i>CNS Drugs</i> , 2014, 28, 835-854.	2.7	82
170	Pharmacoeconomic Outcomes for Pregabalin: A Systematic Review in Neuropathic Pain, Generalized Anxiety Disorder, and Epilepsy from a Spanish Perspective. <i>Advances in Therapy</i> , 2014, 31, 1-29.	1.3	12
171	Does comorbid subthreshold anxiety predict treatment response in depression? Results from a naturalistic cohort study (the CRESCEND study). <i>Journal of Affective Disorders</i> , 2014, 152-154, 352-359.	2.0	10
172	Anticonvulsant activity of pregabalin in the maximal electroshock-induced seizure assay in $\hat{1}\pm 2\hat{1}1$ (R217A) and $\hat{1}\pm 2\hat{1}2$ (R279A) mouse mutants. <i>Epilepsy Research</i> , 2014, 108, 833-842.	0.8	31
173	Pregabalin in acute treatment of anxious depression: A case series. <i>Psychiatry Research</i> , 2014, 215, 246-248.	1.7	5
174	Intellectual disability with co-morbid epilepsy and behavioral disorder: Impact of antiepileptic drugs on behavior. <i>Journal of Pediatric Neurology</i> , 2015, 06, 093-097.	0.0	0

#	ARTICLE	IF	CITATIONS
176	Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms. <i>International Clinical Psychopharmacology</i> , 2015, 30, 265-271.	0.9	11
177	Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4329.	2.0	5
178	Emerging drugs for the treatment of anxiety. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 393-406.	1.0	102
179	Pharmacological treatment for generalized anxiety disorder in adults: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1669-1681.	0.9	61
180	Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors. <i>Annals of General Psychiatry</i> , 2015, 14, 2.	1.2	6
181	Pharmacotherapy for anxiety and comorbid alcohol use disorders. <i>The Cochrane Library</i> , 2020, 2020, CD007505.	1.5	43
182	Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. <i>Journal of Psychopharmacology</i> , 2015, 29, 1047-1060.	2.0	47
183	Benzodiazepines and Anxiety Disorders: From Laboratory to Clinic. , 2016, , .		2
184	The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Generalized Anxiety Disorder. <i>Harvard Review of Psychiatry</i> , 2016, 24, 243-256.	0.9	15
185	A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. <i>Journal of Affective Disorders</i> , 2016, 206, 140-150.	2.0	67
186	Neuropsychiatric Symptoms of Epilepsy. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2016, , .	0.3	12
187	The Role of Antiepileptic Drugs. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2016, , 333-360.	0.3	2
188	Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 351-359.	1.5	14
189	Pregabalin for generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 49-55.	0.9	52
190	Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 41-48.	0.9	8
191	Refractory social anxiety disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, E1-E2.	1.4	2
192	Pregabalin for anxiety in patients with schizophrenia " A randomized, double-blind placebo-controlled study. <i>Schizophrenia Research</i> , 2018, 195, 260-266.	1.1	8
193	The Rodent-versus-wild Snake Paradigm as a Model for Studying Anxiety- and Panic-like Behaviors: Face, Construct and Predictive Validities. <i>Neuroscience</i> , 2018, 369, 336-349.	1.1	36

#	ARTICLE	IF	CITATIONS
194	Oral pregabalin for acute pain relief after cervicofacial surgery: a systematic review. <i>Clinical Oral Investigations</i> , 2018, 22, 119-129.	1.4	7
195	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1109-1172.	1.3	137
196	Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 883-894.	0.9	77
197	Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1057-1070.	0.9	127
198	Effect of valproate and pregabalin on human anxiety-like behaviour in a randomised controlled trial. <i>Translational Psychiatry</i> , 2018, 8, 157.	2.4	34
199	Depression, anxiety and acute pain: links and management challenges. <i>Postgraduate Medicine</i> , 2019, 131, 438-444.	0.9	186
200	Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. <i>Journal of Psychiatric Research</i> , 2019, 118, 73-83.	1.5	34
201	Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs. <i>European Journal of Pain</i> , 2019, 23, 1129-1140.	1.4	12
202	Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study. <i>Pharmacopsychiatry</i> , 2019, 52, 193-202.	1.7	5
203	Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning. <i>Psychological Medicine</i> , 2019, 49, 2692-2708.	2.7	18
204	Treatment Resistance in Anxiety Disorder: Generalized Anxiety Disorder and Social Anxiety Disorder. , 2019, , 207-214.		0
205	Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. <i>Cognitive Behaviour Therapy</i> , 2020, 49, 1-21.	1.9	77
206	Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology. <i>Frontiers in Psychiatry</i> , 2020, 11, 548505.	1.3	36
208	Treatment of diabetic peripheral neuropathy: a review. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 863-872.	1.2	62
209	Trends in new prescription of gabapentinoids and of coprescription with opioids in the 4 nations of the UK, 1993â€“2017. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3349-3353.	1.1	10
210	Treatment of Sleep Disorders in Specific Psychiatric Diseases. , 2021, , 1-30.		1
211	Tranquilizer/Anxiolytics: Pregabalin. , 2021, , 1-16.		0
212	AngststÃ¶rungen. , 2017, , 1857-1932.		6

#	ARTICLE	IF	CITATIONS
213	Neuronal Functions of Auxiliary Calcium Channel Subunits. , 2013, , 29-59.		4
214	Anxiety Disorders and Posttraumatic Stress Disorder. , 2017, , 1341-1351.e5.		4
216	Sleep in anxiety disorders. , 0, , 286-297.		2
217	Psychiatric illness and psychotropic medication use in epilepsy. , 2011, , 165-196.		3
219	Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment, 2007, 3, 185-191.	1.0	41
220	The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatric Disease and Treatment, 2007, 3, 237-243.	1.0	26
221	Pregabalin and Libido- Case Reports. The Open Neuropsychopharmacology Journal, 2011, 5, 8-9.	0.3	5
222	The effectiveness of anticonvulsants in psychiatric disorders. Dialogues in Clinical Neuroscience, 2008, 10, 77-89.	1.8	32
223	Treatment-Refractory Generalized Anxiety Disorder. Psychiatric Annals, 2011, 41, 104-112.	0.1	3
224	Similarities between interstitial cystitis/bladder pain syndrome and vulvodynia: implications for patient management. Translational Andrology and Urology, 2015, 4, 643-52.	0.6	22
225	Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. primary care companion for CNS disorders, The, 2011, 13, .	0.2	20
226	Management of Generalized Anxiety Disorder in Primary Care. Primary Care Companion To the Journal of Clinical Psychiatry, 2010, 12, .	0.6	29
227	Efficacy and safety of premedication with single dose of oral pregabalin in children with dental anxiety: A randomized double-blind placebo-controlled crossover clinical trial. Dental Research Journal, 2015, 12, 528.	0.2	7
228	Oral pregabalin as premedication on anxiolysis and stress response to laryngoscopy and endotracheal intubation in patients undergoing laparoscopic cholecystectomy: A randomized double-blind study. Anesthesia: Essays and Researches, 2019, 13, 97.	0.2	11
229	Maximizing Function and Quality of Life of Patients with Glioblastoma after Surgical Resection: A Review of Current Literature. Journal of Cancer Therapy, 2016, 07, 857-888.	0.1	6
230	Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective. Psychiatry Investigation, 2009, 6, 55.	0.7	11
231	Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms. European Journal of Psychiatry, 2010, 24, .	0.7	14
232	An observational study comparing the efficacy of duloxetine and pregabalin in patients with generalized anxiety disorder. Engrami, 2020, 42, 20-31.	0.1	3

#	ARTICLE	IF	CITATIONS
233	The Pharmacotherapy of Anxiety Disorders. , 2008, , 565-575.		0
234	Angststörungen. , 2008, , 1569-1633.		0
235	New Antiepileptic Drugs in Neuropsychiatric Disorders – Basic Mechanisms Related to Clinical Efficacy. , 2010, , 485-504.		2
236	Model Based Development of an Agent for the Treatment of Generalized Anxiety Disorder. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 325-340.	0.2	0
239	Evaluation of sedative effect and safety of pregabalin in uncooperative children in dental clinic. Iranian Journal of Pediatric Dentistry, 2014, 9, 25-30.	0.0	0
240	Pregabalin in the treatment of anxiety disorders. Psychiatria I Psychologia Kliniczna, 2015, 15, 141-147.	0.3	1
241	Angststörungen. , 2016, , 1-77.		2
242	Efficacy and Tolerability of Pregabalin vs Sertralin in Generalised Anxiety Disorder Concise Communication. Journal of Yoga & Physical Therapy, 2016, 06, .	0.1	0
243	The application of pregabalin in general anxiety disorders treatment. Should one be afraid of high doses?. Psychiatria I Psychologia Kliniczna, 2016, 16, 91-98.	0.3	2
244	Pregabalin at doses of 300 mg/day and higher – benefit and risk balance. Psychiatria I Psychologia Kliniczna, 2017, 17, 208-215.	0.3	0
245	Zentrales Nervensystem. , 2018, , 253-445.		0
246	Generalised anxiety disorder. Clinical Evidence, 2007, 2007, .	0.2	0
247	Generalised anxiety disorder. Clinical Evidence, 2011, 2011, .	0.2	2
248	Pharmacological treatment of diabetic peripheral neuropathy. P and T, 2015, 40, 372-88.	1.0	23
250	Green synthesis of pregabalin-stabilized gold nanoclusters and their applications in sensing and drug release. Archiv Der Pharmazie, 2022, , e2100426.	2.1	7
252	Zentrales Nervensystem. , 2022, , 301-510.		0
253	A single injection of pregabalin induces short- and long-term beneficial effects on fear memory and anxiety-like behavior in rats with experimental type-1 diabetes mellitus. Metabolic Brain Disease, 2022, 37, 1095-1110.	1.4	4
255	Treatment of Sleep Disorders in Specific Psychiatric Diseases. , 2022, , 3955-3984.		0

#	ARTICLE	IF	CITATIONS
256	Tranquilizer/Anxiolytics: Pregabalin. , 2022, , 2083-2097.		0
259	Medications for Anxiety Disorders. , 2023, , 1-68.		0